股票行情快报：五洲医疗（301234）2月26日主力资金净卖出123.06万元

Core Viewpoint - Wuzhou Medical (301234) reported a slight increase in stock price but faced significant declines in net profit and revenue in the latest financial results [2]. Group 1: Financial Performance - For the first three quarters of 2025, Wuzhou Medical's main revenue was 345 million yuan, a year-on-year increase of 0.82% [2]. - The net profit attributable to shareholders was 18.51 million yuan, a year-on-year decrease of 46.09% [2]. - The net profit after deducting non-recurring items was 14.82 million yuan, down 45.3% year-on-year [2]. - In Q3 2025, the company's single-quarter main revenue was 128 million yuan, a year-on-year decrease of 1.51% [2]. - The single-quarter net profit attributable to shareholders was 7.99 million yuan, a decline of 36.39% year-on-year [2]. - The single-quarter net profit after deducting non-recurring items was 6.48 million yuan, down 28.01% year-on-year [2]. - The company's debt ratio stood at 12.32%, with investment income of 3.67 million yuan and financial expenses of -2.07 million yuan [2]. - The gross profit margin was reported at 14.22% [2]. Group 2: Business Model - Wuzhou Medical specializes in the research, production, and sales of disposable sterile infusion medical devices, as well as integrated supply of other diagnostic and nursing medical products [2]. - The company primarily operates through an "ODM + integrated supply" model to meet the one-stop procurement needs of foreign medical device brand companies [2]. Group 3: Market Activity - As of February 26, 2026, Wuzhou Medical's stock closed at 41.74 yuan, with a turnover rate of 1.39% and a trading volume of 9,428 hands, resulting in a transaction amount of 39.59 million yuan [1]. - On the same day, the net outflow of main funds was 1.23 million yuan, accounting for 3.11% of the total transaction amount, while retail funds saw a net inflow of 2.40 million yuan, making up 6.07% of the total [1].